ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
102 announcements with these filters
Medplus Health Services' subsidiary, Optival Health Solutions, received a two-day drug license suspension for a Karnataka store. The financial impact is estimated at ₹0.0029 Crore.
Medplus Health Services' subsidiary, Optival Health Solutions, received regulatory orders suspending drug licenses for three stores for two days due to compliance violations.
MedPlus Health Services' subsidiary, Optival Health, received two-day drug license suspensions for three stores. The total estimated potential revenue loss is ₹0.024 Crore.
ICICI Prudential Mutual Fund acquired 1,75,537 shares of Medplus Health Services Ltd. This purchase brought the Fund's total shareholding to 5.073%.
MedPlus Health Services Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, in compliance with SEBI Listing Regulations.
MedPlus Health Services has filed its 20th Annual Report for FY 2025-26 and scheduled its Annual General Meeting for August 17, 2026.
Medplus Health Services decided to keep the CAPEX plan for a Food Park and Concierge Facility in abeyance. No adverse business impact is expected.
Medplus reported strong revenue growth but faced significant margin pressure from a lower private label mix and rising employee costs due to regulatory changes.
MedPlus reported Q1 FY27 revenue of ₹18,796M (+21.8% YoY) but saw Operating EBITDA decline 10.6% YoY to ₹651M. Strategy focuses on store network expansion, particularly franchisees.
MedPlus Health Services Limited has appointed Mr. Shrenik Soni as the new Company Secretary and Compliance Officer, effective July 21, 2026.
MedPlus approved Rs 130 Crore capex for a food park and wellness facility, plus unaudited quarterly results and the appointment of a new Company Secretary.
Medplus Health Services' subsidiary, Optival Health, faces a two-day drug license suspension at a Karnataka store. Financial impact is estimated at a negligible ₹0.0053 Crore.
MedPlus subsidiary Optival Health Solutions faces a 2-day drug license suspension at a Karnataka store, with a potential revenue loss of ₹0.0053 Crore.
Medplus Health Services Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.
MedPlus subsidiary Optival Health Solutions faced one to two-day drug license suspensions across three Karnataka stores. The estimated total revenue impact is approximately Rs. 1.59 lakhs.
Medplus will hold a Board Meeting on July 21, 2026, to approve Q1 FY27 results. Trading window is closed until July 23, 2026.
Medplus subsidiary received a 5-day drug license suspension in Maharashtra. Potential revenue loss of Rs. 0.75 lacs is quantified for investors.
Medplus subsidiary received a 3-day drug license suspension in Bangalore. Potential revenue loss of Rs 5.13 lacs is quantified for investors.
Medplus subsidiary faces a two-day drug license suspension for one store in Davanagere. The estimated financial impact is 0.008 Crore due to regulatory non-compliance.
Medplus subsidiary Optival Health Solutions faced one-day drug license suspensions at two Karnataka stores. The regulatory action follows violations of the Drugs and Cosmetics Act.
MedPlus subsidiary received two drug license suspension orders for a Karnataka store. This halts operations at the specific location.
MedPlus subsidiary Optival Health Solutions faced one-to-three-day license suspensions at three stores in Karnataka and Andhra Pradesh. Estimated financial impact is Rs 0.0158 Crore.
MedPlus reports drug license suspensions for three stores. The incident causes a minimal potential revenue loss of ₹0.02 Crore.
MedPlus subsidiary Optival Health's Karnataka store faced a one-day drug license suspension. This resulted in a potential revenue loss of ₹0.0046 Crore.
Medplus subsidiary stores in Andhra Pradesh faced drug license suspensions. This results in a total potential revenue loss of ₹0.03 Crore.
MedPlus Health Services announced the completion of tenure of two Independent Directors. This marks a change in board composition with no immediate financial impact.
MedPlus subsidiary received a two-day drug license suspension in Karnataka. The potential revenue loss is Rs 1.48 lacs, with limited financial impact.
MedPlus subsidiary Optival Health Solutions faced a 15-day drug license suspension at its Ongole store. The disruption causes an estimated ₹0.02 Crore revenue loss.
MedPlus subsidiary Optival Health Solutions received drug license suspensions for two Telangana stores. The temporary closures result in a combined potential revenue loss of ₹0.01 Crore.
MedPlus Health Services Limited submitted its Annual Secretarial Compliance Report for FY2026. The auditor confirmed full regulatory compliance with no material deviations or fines.